Exelixis, Inc. (EXEL)
53.00
+1.26
(+2.44%)
USD |
NASDAQ |
Jun 09, 15:51
Exelixis SG&A Expense (Quarterly) : 139.60M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Merck & Co., Inc. | 2.70B |
| Catalyst Pharmaceuticals, Inc. | 43.52M |
| Madrigal Pharmaceuticals, Inc. | 268.52M |
| Krystal Biotech, Inc. | 41.01M |
| ACADIA Pharmaceuticals, Inc. | 171.02M |